GoodRx shares edged up 2.8% post-earnings, reflecting a generally steady reaction to solid growth in Pharma Direct and broader platform engagement but without a clear breakout catalyst to push the stock higher.

• Pharma Direct revenue surged 82% year-over-year, fueled by manufacturer-sponsored pricing programs and strong uptake of new GLP-1 therapies such as Wegovy Pill and Ozempic Pill.
• GoodRx accounted for roughly one-third of Wegovy Pill transactions in the first two months post-launch, underscoring its growing influence in the self-pay prescription market.
• The company expanded manufacturer collaborations, including a new program with Viatris for 17 brand medications and a Pfizer-branded storefront offering discounts on 30+ essential drugs.
• Rx Marketplace performance aligned with internal expectations, supported by ongoing e-commerce expansion and direct contracting models.
• Management highlighted evolving healthcare dynamics—widening coverage gaps and elevated out-of-pocket costs—that continue to validate GoodRx’s strategy of improving affordability and access.